Allogene Therapeutics, Inc. (ALLO)
2.07
-0.15
(-6.76%)
USD |
NASDAQ |
Mar 20, 16:00
2.11
+0.04
(+1.93%)
After-Hours: 20:00
Allogene Therapeutics Research and Development Expense (Quarterly) : 25.58M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 12.26M |
| Inovio Pharmaceuticals, Inc. | 9.921M |
| Vaxart, Inc. | 45.15M |
| Capricor Therapeutics, Inc. | 22.88M |
| Agenus, Inc. | 7.511M |